Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23548374 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1MAPK1ALDH1A1TDP1 | |
| SCHEMBL23548373 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1MAPK1ALDH1A1TDP1 | |
| SCHEMBL6824800 | 0.82 | MAPK1 (0.36) | SMN1; SMN2MAPK1ALDH1A1TDP1 | |
| SCHEMBL4994322 | 0.82 | MAPK1 (0.36) | SMN1; SMN2MAPK1ALDH1A1TDP1 | |
| SCHEMBL6824552 | 0.82 | MAPK1 (0.36) | SMN1; SMN2MAPK1ALDH1A1TDP1 | |
| SCHEMBL4998227 | 0.78 | MEN1 (0.34) | SMN1; SMN2 | |
| SCHEMBL6818549 | 0.75 | ALDH1A1 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL21682041 | 0.64 | — | — | |
| SCHEMBL21682106 | 0.64 | — | — | |
| SCHEMBL21389274 | 0.64 | MEN1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3833355-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033288-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3071036-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | Dow AgroSciences LLC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9334273-B1 | Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20030045508-A1 | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| EP-1235834-A1 | (1R,CIS)-4-(4-AMINO-7H-PYRR0L0[2,3- I(D)]PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | disclosed |
| EP-1150988-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150981-A1 | THERAPEUTIC NUCLEOSIDE COMPOUND | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001042255-A1 | (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
| US-6147254-A | Process for resolving mixtures of carbocyclic stereoisomers | GLAXO WELLCOME INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000047581-A1 | THERAPEUTIC NUCLEOSIDE COMPOUND | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047591-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
| EP-0946496-A2 | PROCESS FOR RESOLVING MIXTURES OF CARBOCYCLIC STEREOISOMERS | GLAXO GROUP LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024741-A2 | PROCESS FOR RESOLVING MIXTURES OF CARBOCYCLIC STEREOISOMERS | GLAXO GROUP LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | SMN1; SMN2 3236/4885L3MBTL1 4170/4885MAPK1 1408/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | SMN1; SMN2 3236/4885L3MBTL1 4170/4885MAPK1 1408/4885 |
| US-20030045508-A1 | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral | MAVS, ZC3HAV1, SARS1 | SMN1; SMN2 1700/4885L3MBTL1 2288/4885MAPK1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.